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MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that play essential roles in a variety 
of biological processes including apoptosis, proliferation and differentiation. Altered expression of 
miRNAs in head and neck cancer has been reported, but the consequences of aberrant expression of 
specific miRNAs on cancer pathways remain vague. Therefore, it is important to identify and elucidate 
pathways that may be regulated by specific miRNAs in this disease. miR-181a was up-regulated in head 
and neck versus normal tissues, thus pathway analysis was performed to profile the changes in the 
activities of ten signaling pathways relevant to cancer influenced by down-regulation of miR-181a. 
Expression of four pathway reporters were significantly increased (p53/DNA damage, TGFβ, MAPK/ERK 
and MAPK/JNK), while expression of two pathway reporters were decreased (Wnt and NFkB) upon miR-
181a down-regulation. Notch, Myc/Max, hypoxia and cell cycle/pRB-E2F pathways were not significantly 
affected by miR-181a down-regulation. This study provides insight into the understanding of miRNA 
regulation on major cancer pathways. 
 






Head and neck cancer is the sixth most common cancer 
affecting men globally (Parkin et al., 2005) and it includes 
cancers that originated from nasopharynx, oropharynx, 
hypopharynx, larynx, oral cavity, lips, nose and paranasal 
sinus, thyroid, as well as salivary glands. A total of 2884 
cases of head and neck cancer were reported in 
Peninsula Malaysia in the year 2006, with 34% of overall 
cases contributed by nasopharyngeal cancer. The world-
wide five-year relative survival rate is less than 50%, which 
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colorectal, cervix and breast origin and this has remained 
unchanged for more than three decades (Jemal et al., 
2011). Poor prognosis regardless of advances in treat-
ment can be attributed to late presentation, failure of 
advanced disease stage to respond to treatment, as well 
as lack of proper markers for screening. The understanding 
of the pathways underlying this cancer is expanding 
(Hunter et al., 2005) although there is still much to learn 
about the accurate mechanisms (Tran et al., 2010). 
Recently, non-coding genes such as microRNAs (miRNAs) 
are regarded as regulators in many molecular pathways 
underlying various cancers (Tran et al., 2010). 
miRNAs are endogenous, small, non-coding RNAs of 
17 to 25 nucleotides that regulate almost 30% of human 
genes   by   inducing    mRNA  cleavage   or  translational  




suppression at the post-transcriptional level (Bartel, 
2009). Firstly discovered in Caenorhabditis elegans, its 
crucial involvement in various cancer-related cellular pro-
cesses such as cell differentiation, cell division, apoptosis 
and cell cycle regulation (Miska, 2005) made this molecule 
worth studying in head and neck cancer. miRNAs paired 
with their target messenger RNA (mRNA) through imper-
fect pairing with the 3′ untranslated region (UTR) resulted 
in their destabilization or ribosomal blockade (Bushati 
and Cohen, 2007). At the moment, miRNAs deregulation 
is considered a hallmark of cancer (Calin and Croce, 
2006), in which they can function as oncogenes or tumor 
suppressors (Croce, 2009). Current miRNAs database 
showed that 1,424 human miRNAs have been deposited 
in miRBase release 17.0 (http://www.mirbase.org). 
Although, altered expression of miRNAs in head and 
neck cancer has been reported (Ramdas et al., 2009; Hui 
et al., 2010, Nurul-Syakima et al., 2011), their biological 
function remains largely unknown and the consequences 
of aberrant expression of specific miRNAs on cancer 
pathways remain unclear. Thus, one of the vital priorities 
is the need to identify and elucidate pathways that may 
be regulated by specific miRNAs in this disease. Previous 
global miRNA expression study showed that expression 
level of miR-181a is up-regulated in head and neck 
cancer tissue versus normal tissue (Nurul-Syakima et al., 
2011). In addition, other miRNA studies in head and neck 
cancers also revealed the up-regulation of the miR-181 
family (Kozaki et al., 2008; Wong et al., 2008; Cervigne et 
al., 2009). Furthermore, miR-181a up-regulation is also 
observed in carcinoma of breast (Calin and Croce, 2006) 
and ovary (Iorio et al., 2007). This up-regulation suggests 
that miR-181a is an oncogenic miRNA (oncomiR). On the 
contrary, miR-181a expression is down-regulated in glioma, 
suggesting its role as a tumor suppressor (Shi et al., 
2008). Hence, this study aims to investigate and validate 
the effect of miR-181a down-regulation on major cancer 
pathways in head and neck cancer. 
 
 
MATERIALS AND METHODS 
 
Cell line and culture condition 
 
The human hypopharyngeal FaDu (HTB-43) cell line was 
purchased from the American Type Culture Collection (ATCC, 
Manassas, VA) and was maintained with Minimal Essential Medium 
(MEM) with Earle’s salt (Nacalai Tesque, Tokyo, Japan) 
supplemented with 10% fetal bovine serum (FBS) (Nacalai Tesque, 
Tokyo, Japan) and 100 mg/L penicillin/streptomycin (Invitrogen, 
Carlsbad, California) in a 37°C incubator with humidified 5% CO2 
(Galaxy R+ CO2 Incubator; RS Biotech Laboratory Equip-ment Ltd., 
Irvine, Scotland, UK). 
 
 
miR-181a hairpin inhibitor transfection 
 
The biological effects of miR-181a down-regulation was assessed 
by transfecting FaDu with human miRIDIAN miR-181a hairpin 
inhibitor and inhibitor negative controls (Dharmacon, Lafayette, CO) 





CO) according to the manufacturer’s instructions. A total of 7 × 10
4
 
cells were plated in 96 well plates a day prior to transfection and 
were transfected with 25 nM of miR-181a hairpin inhibitor or 25 nM 
negative control using 0.2 µL transfection reagent per well. The 
cells were incubated at 37°C with 5% CO2. 
 
 
Validation of miR-181a down-regulation using qRT-PCR 
 
Real time reverse transcription polymerase chain reaction (qRT-
PCR) was utilized to assess expression level of miR-181a after its 
down-regulation to validate its inhibition. After 72 h of transfection, 
cells were harvested and total RNA including miRNA was extracted 
using innuPREP microRNA Isolation Kit (Analytik Jena, Jena, 
Germany). The total RNAs were quantified using 
BioPhotometer (Eppendorf, Hamburg, Germany) and further 
analyzed by electrophoresis in a denaturing gel to assess the RNA 
integrity. qRT-PCR was performed using the NCode™ EXPRESS 
SYBR
®
 GreenER™ miRNA qRT-PCR Kit Universal (Invitrogen, 
Carlsbad, CA, USA) with 10 pmol primers. RNU-48 was used as 
normalization control and reference gene. The cDNA was 
synthesized from 1 µg total RNA according to the manufacturer’s 
protocol.  
miR-181a-specific primers were designed using Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). The qPCR reaction 
was run in triplicates using Rotorgene 6000 (Qiagen, Valencia, CA, 
USA) in a 20 µL total volume according to manufacturer’s protocol 
with adjustment of annealing time to 15 s. The qRT-PCR 
amplification products were subsequently analyzed by melting 
curve analysis and confirmed by 1.8% agarose gel electrophoresis. 
A negative control without cDNA template was included to assess 
the specificity of the qPCR reaction. Fold change of miR-181a 
expression was analyzed using 2
-∆∆Ct 
method (Schmittgen and 
Livak, 2008). This method was validated by using protocol descri-
bed by Livak and Schmittgen (2001). Primer sequences for qRT-
PCR reaction are summarized in Table 1. 
 
 
Dual luciferase pathway reporter transfection 
 
Pathway analysis was performed using the Cignal Finder 10 
Pathway Reporter Arrays (SA Biosciences, Fredrick, MD) according 
to the manufacturer’s instructions. Reverse transfection protocol 
was implemented. Briefly, a day before transfection, cells were 
passed 1:4 in a 25 cm
3
 flasks and were incubated at 37°C with 5% 
CO2 overnight. Then, 100 ng of each dual luciferase Cignal 
transcription factor-responsive reporter, negative and positive 
control constructs were diluted in serum-free MEM along with miR-
181a hairpin inhibitor and inhibitor negative control. The diluted 
nucleic acids were mixed with the diluted 0.3 µL DharmaFECT 1 
transfection reagent, delivered to 2 × 10
5
 cells resuspended in Opti-
MEM
®
 (Invitrogen, Carlsbad, CA, USA) containing 5% FBS and 1% 
non-essential amino acids (NEAA; Invitrogen, Carlsbad, CA, USA) 
in a 96 well plate and was incubated in a 37°C incubator with 5% 
CO2. After transfection for 24 h, culture medium was changed to the 
complete growth medium (MEM supplemented with 10% FBS, 0.1 
mM NEAA, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 
μg/ml streptomycin) and was further incubated for another 48 h. 





After 72 h, cells were harvested and luciferase activity was 
measured using the Dual-Glo Luciferase Assay system (Promega, 
Madison, WI) on a Panomics luminometer (Panomics, Inc., 
Fremont, CA). The firefly/Renilla activity ratio generated from the 
transcription factor-responsive reporter transfections was divided by  




Table 1. Sequence of qRT-PCR primers used in this study.  
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the firefly/Renilla activity ratio generated from the negative control 
transfections to obtain the relative luciferase units. Subsequently, 
fold change of reporters’ expression between miR-181a hairpin 
inhibitor transfectant and their negative control was calculated from 





The results are expressed as mean ± standard error (SE). 
Statistical analyses were performed with SPSS version 16 (SPSS, 
Chicago, Illinois, USA) and statistical significances were determined 












 method that was employed in this study 
demands for validation before being used in qRT-PCR 
analysis (Livak and Schmittgen, 2001). In validation of 2
-
∆∆Ct
 method, primers’ efficiencies were determined and a 
plot of the log cDNA dilution versus ∆Ct was made for 
each primer set. qRT-PCR was performed on 10-log 
dilution series of cDNA and a standard curve was 
generated in Rotor-Gene 6000 Series software for each 
primer pairs (Figure 1A and B). Data were then exported 
to Excel 2007 (Microsoft, Seattle, WA) and ∆Ct was 
calculated (Ct miR-181a – Ct RNU-48) for each cDNA dilution. 
Graph log cDNA dilution versus ∆Ct was plotted and the 
slope of the line was determined. As shown in Figure 1C, 
the absolute value of the slope (R
2
) was close to zero, 
concluding that the efficiencies of the target and 
reference gene are equal. Thus, the ∆∆Ct calculation for 
the relative quantification of miR-181a can be used to 
analyze the qRT-PCR data.  
 
 
qRT-PCR validation of miR-181a down-regulation  
 
Expression level of miR-181a after transfection with its 
inhibitor was assessed by qRT-PCR and was compared 
to the negative control. After calculating fold change of 
expression using 2
-∆∆Ct
, there was ~22 fold reduction of 
miR-181a expression in cells transfected with 25 nM miR-
181a hairpin inhibitor compared to negative control (Figure 
2). 
miR-181a down-regulation resulted in various cancer 
pathways alteration 
 
To determine the signaling pathways induced upon miR-
181a down-regulation, a transcription factors array con-
sisting of 10 dual-luciferase reporters assays were used. 
Each of the reporters encodes for an inducible transcription 
factor responsive firefly luciferase reporter and 
constitutively expressing Renilla construct in 40:1 ratio. 
Experimental reporter was represented by firefly luci-
ferase, while normalization reporter was represented by 
Renilla luciferase. Student t-test showed that there were 
six pathways significantly affected by miR-181a down-
regulation (Table 2). As summarized in Figure 3, expres-
sion of four pathway reporters (p53/DNA damage, TGFβ, 
MAPK/ERK and MAPK/JNK) were increased, while two 
pathway reporters (Wnt and NFkB) were decreased upon 
transfection. Notch, Myc/Max, hypoxia and cell cycle/pRB-
E2F pathways were not significantly affected by miR-





Being a master regulator of gene expression and cellular 
pathways, miRNAs are considered to possess great 
therapeutic potential (Nelson and Weiss, 2008). miRNAs 
deregulation was revealed in different disease conditions 
including head and neck cancer. Inhibition of a single 
miRNA can result in an enormous effect within a cell and 
can significantly modify the cellular phenotype due to its 
ability to target several genes directly and indirectly 
(Visone and Croce, 2009). Hence, miRNA down- or up-
regulation can be a key factor in the treatment of human 
diseases (Liu et al., 2008). However, many aspect need 
to be clarified before a miRNA can serve as a therapeutic 
agent, including understanding of the molecular pathway 
underlying disease progression. Thus, this study aimed to 
investigate the effect of miR-181a down-regulation on 
major cancer pathways in head and neck cancer. To 
identify the major pathways that are affected by this 
miRNA, a reporter assay was performed and p53/DNA 
damage, TGFβ, MAPK/ERK, MAPK/JNK, Wnt and NFκB 
pathways were found to be significantly influenced by 
miR-181a down-regulation. These pathways play impor-
tant roles in head and neck carcinogenesis (Blons and 
Laurent-Puig,  2003;  Uraguchi et al., 2004; Levy and Hill, 








 validation. (A) and (B), Efficiency graph of each primer pairs used in qRT-PCR. Serial dilutions of cDNA were amplified by qRT-PCR using miRNA specific 
primers. Good efficiency is denoted by value of 90 to 110% (0.9 to 1.1) with slope of the standard curve (M) approximately -3.3 (± 0.1) and R
2
 > 0.99. R
2
 is a statistical term 
that shows how good one value is at predicting another and its value of >0.99 provides good confidence in correlating two values. (C) cDNA was synthesized from 1 µg 
total. 10-log dilutions were performed and were amplified by qRT-PCR. ∆Ct was determined and plotted against log cDNA dilutions. These data were fitted using least-
squares linear regression analysis and observed for R
2




2006; Squarize et al., 2006; Stadler et al., 2008). 
One of the most frequent alterations in head and 
neck cancer is the disruption of the p53 pathway 
through mutations, losses of heterozygosity (LOH) 
or  interaction  with  viral  proteins  such as human 
papilloma virus (HPV) (Blons and Laurent-Puig, 
2003). The p53 protein is involved in the repairs of 
the cellular integrity after DNA damage and when 
activated, the p53 protein can induce growth arrest 
and cell death (Nylander et al., 2000). miR-181a is 
highly expressed in head and neck cancer versus 
normal tissues (Nurul-Syakima et al., 2011), thus, 
this miRNA is an oncomiR candidate. Inhibition or 
down-regulation of miR-181a expression might have 
therapeutic  potential  as  this  study  showed  that






Figure 2. Expression level of miR-181a in cells treated with miR-181a hairpin inhibitor and negative control. 




Table 2.  Ten cancer pathways involved in this study.  
 
Pathway Transcription factor Expression Fold change p-value 
Wnt TCF/LEF ↓ 0.262 0.012 
Notch RBP-Jκ - 1.276 0.48 
p53/DNA damage p53 ↑ 3.727 0.023 
TGFβ SMAD2/3/4 ↑ 3.057 0.034 
Cell cycle/pRB-E2F E2F/DP1 - 0.509 0.13 
NFκB NFκB ↓ 0.551 0.041 
Myc/Max Myc/Max - 0.54 0.345 
Hypoxia HIF1A - 0.607 0.472 
MAPK/ERK Elk-1/SRF ↑ 3.441 0.001 
MAPK/JNK AP-1 ↑ 1.742 0.006 
 
Significance value (p) was determined by Student’s t-test. p<0.05. 






Figure 3. Pathway reporter assay of key response elements in 10 major cancer-related pathways. 
The ratio of reporter signals between cells treated with miR-181a hairpin inhibitor and negative 




miR-181a down-regulation led to increased expression of 
p53 transcription factor. In the past few years, solid 
connections between the miR-34 family and p53 tumor 
suppressor network in the regulation of apoptosis have 
been demonstrated (He et al., 2007; Hermeking, 2007). 
More recent in-depth study showed that the down-
regulation of miR-34a expression in the livers of methyl-
deficient rats could contribute to a carcinogenic process 
by inhibition of the p53 pathway, thus compromising the 
cellular apoptotic program (Tryndyak et al., 2009). In 
combination with the current study, these findings provi-
ded evidence of miRNA involvement in p53 pathway. 
Generally, transforming growth factor beta (TGFβ) 
signaling pathway regulates tumor development via a 
tumor cell‑autonomous mechanism or through tumor–
stroma interaction, and has the ability to suppress or 
promote tumor depend on cellular context (Ikushima and 
Miyazono, 2010). Alteration in TGFβ signaling is central 
to tumorigenesis and tumor progression by affecting the 
cellular process including cell proliferation and cell 
invasion (Blobe et al., 2000). Absence or decreased 
SMAD4 expression and the signal transducers of the 
TGFβ family signaling cascade (Hata and Davis, 2009) 
has been found in various cancers, including pancreatic, 
colorectal and head and neck cancer (Bornstein et al., 
2009). Interestingly, the SMADs also play a regulatory 
role in the processing of miRNA in the nucleus. miRNA 
involvement  in TGFβ signaling pathway was demonstrated 
by Kong et al. (2008). TGFβ was found to induce miR-
155 expression and promoter activity through SMAD4, 
while knockdown of miR-155 suppressed TGFβ-induced 
epithelial-mesenchymal transition (EMT), tight junction 
dissolution, cell migration and invasion in breast cancer 
(Kong et al., 2008). In addition, miR-106b and miR-93 
impair TGFβ-induced cell cycle arrest while miR-25 
cooperates with miR-106b and miR-93 in preventing the 
onset of TGFβ-induced apoptosis in gastric cancer 
(Petrocca et al., 2008). In this study, miR-181 down-
regulation resulted in increased expression of TGFβ 
transcription factors (SMAD2/3/4). Since SMADs expres-
sion was reduced in cancer, their increased expression 
upon miR-181a down-regulation in this study was probably 
due to inhibition of cancer cell growth. 
Mitogen-activated protein kinase (MAPK) signaling 
pathways are involved in the regulation of gene expres-
sion, mitosis, proliferation, motility, metabolism and 
apoptosis (Werlen et al., 2003). Conventional MAPKs 
comprised of three family members: the extracellular 
signal-regulated kinase (ERK), c-Jun NH2-terminal kinase 
(JNK) and p38-MAPK (Wada and Penninger, 2004). The 
MAPK/ERK pathway is activated in response to many 
mitogens and generally regulates cell proliferation and 
cell cycle (Schmidt et al., 2000). Due to its ability to 
promote proliferation and increase cell survival, Balmanno 
and Cook (2009) have proposed an oncogenic property 





activation of MAPK/ERK pathway resulted in the 
promotion of apoptosis, suggestive of an anti-proliferative 
role (Martin and Pognonec, 2010). JNKs (also known as 
stress-activated protein kinases; SAPKs) are ubiquitously 
expressed and the MAPK/JNK pathway participates in 
many diverse intracellular signaling pathways that control 
various cellular processes including cell growth, 
differentiation, transformation or apoptosis (Johnson and 
Lapadat, 2001). MAPK/JNK activation generally leads to 
apoptosis promotion; however, like MAPK/ERK, in certain 
conditions it can also support cell survival or tumor pro-
gression (Katz et al., 2007). In this study, the signals of 
MAPK/ERK and MAPK/JNK reporters were both signifi-
cantly increased after miR-181a down-regulation, thus 
suggesting that they were activated upon inhibition of 
miR-181a in head and neck cancer cell line. These 
findings support tumor suppressive ability of the two 
pathways. However, due to their dual potential in cancer 
progression, further investigation is required. Among 
other miRNAs that are found to be involved in MAPK 
signaling pathways are miR-199* (Kim et al., 2008), miR-
21 (Thum et al., 2008), miR-221/miR-222 (Terasawa et 
al., 2009) and miR-34a (Ichimura et al., 2010).  
Wnt signaling commences proliferation, dedifferentia-
tion and EMTs in various types of carcinoma cells 
(Pannone et al., 2010). Increased Wnt expression and 
signaling hasten the progression of carcinomas via 
activating EMTs and local invasiveness (Uraguchi et al., 
2004). Therefore, therapeutic inhibition of Wnt and its 
signaling pathway serve as a valuable approach to stop 
the progress of head and neck progression (Molinolo et 
al., 2009). Decreased expression of Wnt pathway reporter 
was observed in this study after down-regulation of miR-
181a, suggesting its potential usage in head and neck 
cancer therapy. Other miRNAs that appear to regulate 
Wnt signaling pathway includes miR-8 and miR-27. The 
miR-8 family members function as a negative regulator of 
Wnt signaling through their evolutionarily conserved role 
in regulating the pathway (Kennell et al., 2008). Meanwhile, 
Wang and Xu (2010) found out that miR-27 promotes 
osteoblast differentiation by modulating Wnt signaling, 
thus offering a novel target for the development of pre-
ventive or therapeutic agents against osteogenic disorders. 
Nuclear factor κB (NFκB) pathway represents a 
cascade responsible for cell growth and maintenance of 
cellular integrity (Yamamoto and Gaynor, 2001) by 
protecting the cells against xenobiotic injury, as well as 
ensuring ample nutrition and oxygenation via angiogenesis 
(Kato et al., 2000; Xiong et al., 2004). Many evidences 
implicate the NFκB pathway in the pathology of head and 
neck cancer (Tamatani et al., 2001; Zhang et al., 2005). 
In a study done by Lun and colleagues, constitutively 
activated NFκB pathway promotes tumor cell growth (Lun 
et al., 2005). Their findings imply that therapies that 
incorporate inhibitors of the NFκB pathway are worth 
considering. In this study, down-regulation of miR-181a in 
head  and  neck cancer cell lines showed inhibitory effect 
against   NFκB   pathway,   further  strengthening  the  thera- 




peutic value of this miRNA. NFκB pathway is also found 
to be regulated by miR-146a (Taganov et al., 2006), miR-
221/222 (Galardi et al., 2011) and miR-27b* (Thulasingam 
et al., 2011). 
As disease-specific miRNAs are identified, the 
validation of targets within a disease pathway of interest 
may lead to novel therapeutic strategies. This study prov-
ided insights of the influence of miR-181a on major 
cancer pathways in a head and neck cancer cell line 
model. However, more researches are warranted in order 
to gain clear understanding on its regulation in this 
cancer. Due to its short size (17 to 25 nucleotides), a 
miRNA can have several binding site on the target gene. 
More also, different target binding sites may have 
different effect on its regulation, thus it is important to 
validate miRNA/mRNA target pairs. Finally, utilization of 
animal model to study the effect of miRNA down-regulation 
is essential in order to elucidate its therapeutic potential 
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